Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIDRA 21
Description: Inhibits AMPA desensitization
Chemical Name: 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide
Purity: ≥98% (HPLC)
Biological Activity for IDRA 21
Inhibits AMPA receptor desensitization and enhances cognition by a related mechanism. More able to cross the blood-brain barrier than cyclothiazide (Cat. No. 0713).
Technical Data for IDRA 21
| M. Wt | 232.68 |
| Formula | C8H9ClN2O2S |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 22503-72-6 |
| PubChem ID | 3688 |
| InChI Key | VZRNTCHTJRLTMU-UHFFFAOYSA-N |
| Smiles | CC1NC2=C(C=C(Cl)C=C2)S(=O)(=O)N1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for IDRA 21
References for IDRA 21
References are publications that support the biological activity of the product.
Impagnatiello et al (1997) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide: a partial modulator of AMPA receptor desensitization devoid of neurotoxicity. Proc.Natl.Acad.Sci.U.S.A. 94 7053 PMID: 9192690
Thompson et al (1995) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc.Natl.Acad.Sci.U.S.A. 92 7667 PMID: 7644474
Zivkovic et al (1995) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21): a benzothiadiazine derivative that enhances cognition by attenuating DL-α-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J.Pharmacol.Exp.Ther. 272 300 PMID: 7815345
View Related Products by Target
View Related Products by Product Action
Keywords: IDRA 21, IDRA 21 supplier, inhibitors, inhibits, AMPA, receptor, desensitization, desensitisation, Glutamate, Receptors, iGlur, Ionotropic, IDRA21, 1219, Tocris Bioscience
Citations for IDRA 21
Citations are publications that use Tocris products.
Currently there are no citations for IDRA 21.
Reviews for IDRA 21
There are currently no reviews for this product. Be the first to review IDRA 21 and earn rewards!
Have you used IDRA 21?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.